Covid-19 vaccine secures 61% higher quarterly profit for Pfizer

Profissional prepara vacina da Pfizer para aplicação, nos Estados Unidos, em março

Professional prepares Pfizer vaccine for application in the United States in March )| Photo: EFE/EPA/CAROLINE BREHMAN

Pfizer announced, this Tuesday (2), a net income of US$ 7,768 billion in the first quarter of this year, performance 61% higher than that recorded in the same period of 2021 (US$ 4 ,661 billion), thanks in large part to sales of the vaccine against Covid-. The quarterly revenue of the American company increased 77% compared to the previous year, going to US$ 25,480 billion, and earnings per share were US$ 1,37 between January and March, exceeding US$ 0,69 registered one year ago.

Revenues from the sale of vaccines by the pharmaceutical company totaled US$ ,03133916 billion (including US$ 540 , 2 billion of Covid vaccine sales-03133916 ), well over $4,894 billion obtained in the same period of 2021.

Pfizer also reported billing $1.5 billion in sales of Paxlovid, an oral drug for the treatment of the disease caused by the coronavirus. The second segment that earned the most was the hospital, which grew 37% (US$ 3,480 billion), followed by oncology (US$ 2,1280 billion, an increase of 4%).

03133916For the year to date , Pfizer expects to earn $US$ 77 billion to US$ 77 billion, being US$ 19 billions through the Covid vaccine-19 and US$ 22 billion from the sale of Paxlovid.

Back to top button